#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.
Jim Otvos, a biophysical chemist, discusses his pioneering work in NMR spectroscopy to measure lipoprotein particles, including LDL-P. He explains how this technology evolved to provide insights into metabolic health, inflammation (GlycA), insulin resistance (LP-IR, DRI), and the Metabolic Vulnerability Index (MVX), which predicts mortality risk even in healthy young adults.
Deep Dive Analysis
16 Topic Outline
Introduction to Jim Otvos and NMR Spectroscopy
Origin Story: From Cancer Test to Lipoprotein Measurement
How Standard Lipid Panels Measure Cholesterol
NMR Spectroscopy: Measuring Particle Size and Concentration
LDL Particle Number vs. Particle Size for Cardiovascular Risk
Discordance Between LDL-C and LDL-P in Risk Assessment
LP-IR Score for Insulin Resistance and Diabetes Prediction
Commercialization Challenges and Future of NMR Diagnostics
Metabolic Vulnerability Index (MVX) Development and Components
GlycA as a Marker for Systemic Inflammation
MVX and Longevity: Predicting Mortality Risk
MVX in Young, Healthy Adults and Premature Mortality
Potential Clinical Applications of MVX
ApoB vs. LDL-P and Barriers to Adoption
Interpreting CETP Inhibitor Effects on Lipoproteins
Future of NMR Diagnostics and Clinical Translation
6 Key Concepts
Nuclear Magnetic Resonance (NMR) Spectroscopy
A technique that uses magnetic fields and radio waves to detect signals from atomic nuclei (like hydrogen protons) in molecules. Different chemical environments cause signals to appear at different frequencies, allowing for structural determination and, in this application, the quantification of lipoprotein particles based on their size-dependent signal shifts.
LDL Particle Number (LDL-P)
A measure of the total concentration of low-density lipoprotein particles in the blood, reported in nanomoles per liter. It reflects the number of "packages" carrying cholesterol, which is a more accurate predictor of cardiovascular risk than the mass of cholesterol contained within those particles (LDL-C).
Lipoprotein Insulin Resistance (LP-IR) Score
A composite score derived from six VLDL, LDL, and HDL subclass concentration parameters measured by NMR. It ranges from 0 to 100, with higher scores indicating greater insulin resistance and a higher likelihood of future type 2 diabetes.
GlycA
An NMR-derived biomarker that measures the glycan (carbohydrate) decoration on acute phase proteins in the blood. It serves as a stable and reliable indicator of systemic, chronic low-grade inflammation, offering advantages over more volatile markers like hs-CRP.
Metabolic Vulnerability Index (MVX)
A composite score comprising small HDL particle number, GlycA, citrate, and the three branched-chain amino acids (leucine, isoleucine, valine). Ranging from 0 to 100, a higher MVX score indicates increased metabolic frailty and a significantly elevated risk of short-term and premature mortality, independent of age or existing chronic diseases.
Malnutrition Inflammation Syndrome (MIS)
A condition characterized by both malnutrition and chronic inflammation, often observed in patients with acute diseases like kidney disease or heart failure. MVX components like low branched-chain amino acids and high GlycA reflect aspects of this syndrome, linking metabolic dysregulation to increased mortality risk.
10 Questions Answered
LDL-C measures the mass of cholesterol within LDL particles, while LDL-P measures the actual number of LDL particles (packages) in the blood, which is a more direct indicator of cardiovascular risk.
Studies show that when LDL-C and LDL-P are discordant, cardiovascular risk consistently tracks with the LDL particle number, not the cholesterol mass, suggesting that the number of atherogenic particles is more critical than the amount of cholesterol they carry.
No, the idea that large LDL particles are benign is fallacious; individuals with conditions like familial hypercholesterolemia (FH) have very high levels of large LDL particles and face extremely high cardiovascular risk.
NMR spectroscopy detects signals from the terminal methyl groups of fatty acid chains within lipoprotein particles. Larger particles produce signals at slightly lower frequencies, and smaller particles at slightly higher frequencies, allowing for the differentiation and quantification of various size subspecies.
The LP-IR score, derived from NMR analysis of lipoprotein subclass concentrations, can detect insulin resistance and predict type 2 diabetes risk years before glucose levels become elevated, offering an opportunity for earlier intervention.
GlycA is an NMR-derived biomarker that reflects the glycan decoration on acute phase proteins, serving as a stable measure of systemic inflammation. Unlike hs-CRP, it is less volatile and provides a more consistent indicator of chronic low-grade inflammation.
MVX is a composite score from NMR analysis that integrates markers of inflammation (GlycA, small HDLP) and metabolic malnutrition (citrate, branched-chain amino acids). It is a powerful predictor of short-term and premature all-cause mortality, even in healthy young adults, indicating metabolic frailty.
Surprisingly, MVX scores are virtually unassociated with age; the distribution of MVX scores in healthy 30-year-olds is almost identical to that in healthy 60-year-olds, suggesting that metabolic vulnerability can be present early in life.
Despite its efficiency and comprehensive information, NMR diagnostics face commercialization challenges due to the high initial cost of analyzers, the lack of incremental reimbursement for additional "free" information, and the inertia of large IVD companies to adopt new, exotic platforms.
Both ApoB and LDL-P are considered superior to LDL-C for assessing and managing cardiovascular risk. While ApoB is a single measure of all ApoB-containing particles, NMR can provide additional information like triglyceride-rich lipoprotein particles (TRLP) and subclass details, though the clinical utility difference between ApoB and LDL-P for risk assessment is often minimal.
6 Actionable Insights
1. Prioritize LDL Particle Number or ApoB
When managing cardiovascular risk, focus on lowering LDL particle number (LDL-P) or ApoB rather than just LDL cholesterol, as many people achieve low LDL-C but not adequately low LDL-P/ApoB, indicating a need for more aggressive lowering.
2. Address Insulin Resistance Early
Intervene on insulin resistance before glucose levels rise to pre-diabetic or diabetic ranges, as significant beta cell damage may have already occurred by the time hyperglycemia is detected. The LPIR score or Diabetes Risk Index (DRI) can help identify this early.
3. Don’t Dismiss Large LDL Particles
Dispel the misconception that large, “fluffy” LDL particles are benign; individuals with familial hypercholesterolemia (FH) often have high levels of large LDL particles and face severe cardiovascular risk. The number of particles, not their size, is the primary driver of risk.
4. Consider MVX for Short-Term Mortality Risk
Utilize the Metabolic Vulnerability Index (MVX) as a powerful predictor of short-term mortality, especially in high-risk populations, as it can reveal metabolic frailty even in the absence of overt physical frailty.
5. Use GlycA for Stable Inflammation Monitoring
Employ GlycA as a stable and reliable biomarker for systemic inflammation, as it is less volatile than hs-CRP and reflects both acute phase protein levels and glycan decoration, offering a consistent measure of chronic low-grade inflammation.
6. Recognize Discordance in Lipid Markers
Be aware that LDL cholesterol and LDL particle number can be discordant, particularly in individuals with metabolic syndrome, where LDL-P often tracks higher than LDL-C, indicating increased cardiovascular risk.
6 Key Quotes
The challenge is that people with small, dense LDL at a given level of LDL cholesterol have more LDL particles. Their LDL P is higher than would have been imagined from the LDL cholesterol measurement.
Jim Otvos
This idea that somehow fluffy, large LDL particles are not to worry about or benign is completely fallacious.
Jim Otvos
Whenever there's a discrepancy in one direction or another, the cardiovascular risk tracks with the particle number, not the cholesterol.
Jim Otvos
If you don't know that you're insulin resistant, you're waiting for the easily measured glucose to become elevated. And now, once that happens, you've lost about 50% of your beta cell function.
Jim Otvos
MVX scores are virtually unassociated with age.
Jim Otvos
This is something that has to do with dying, not getting the diseases that cause the death.
Jim Otvos